MetaSystems proudly announces the opening of our first subsidiary in the Southern hemisphere. The new office is located in Buenos Aires, Argentina and bears the name MetaSystems Latinoamérica SAS (MetaSystems LatAm). The foundation has been the response to the growing demand on technical knowledge and 'know how' experienced in the last years all over the Latin American territories. MetaSystems LatAm takes care for the organization of sales, support, and customer relation activities in all countries in Latin America. It will manage distributor companies and contacts in the region, and it will facilitate communication between end-users, distributors and headquarters in Germany.
XL t(9;11) MLLT3/KMT2A DF
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl
The KMT2A (previous name ´MLL´) gene, located on chromosome 11q23, is rearranged in about 10% of all acute leukemia patients. Most of them suffer from acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), only a minority shows mixed lineage leukemia which has given the gene its original name ´MLL´. In infants, the incidence of KMT2A rearrangements in leukemia is 70-80%. KMT2A encodes a nuclear protein with methyltransferase activity and is part of multiprotein complexes involved in the regulation of target genes essential during early development and hematopoiesis. Today, more than 80 translocation partners of KMT2A have been identified. Translocations are resulting in in-frame fusions between the KMT2A part N-terminal to the break point cluster region and the respective fusion partners. The most common translocation partners in KMT2A associated leukemia, in the order of their prevalence are AFF1, MLLT3, MLLT1, MLLT10, ELL and AFDN.
KMT2A is involved in about 3-5% of adult de novo AML cases and the most common aberration in this subgroup is t(9;11)(p22;q23) involving the MLLT3 gene. Pediatric patients carrying this aberration do have a favorable outcome which is comparable to AML patients without KMT2A involvement. FISH is described as a reliable method for the identification of t(9;11).
- Acute Lymphoblastic Leukemia (ALL)
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange colocalization/fusion signals (2GO) resulting from a reciprocal translocation between the respective loci.
- Cavazzini et al (2006) Haematologica 91:381-385
- Meyer et al (2013) Leukemia 27:2165-2176
- Winters and Bernt (2017) Front Pediatr 5:doi:10.3389/fped.2017.00004